This white paper explores how GLP-1 therapies are transforming obesity treatment in Australia and reshaping the healthcare landscape. IQVIA highlights that obesity is now the country's leading modifiable risk factor, with more than one million Australians using GLP-1-based medications through a rapidly growing private market. The report examines consumer behaviors, prescribing trends, competitive dynamics between leading manufacturers, and the expanding pipeline of obesity therapies targeting related conditions such as cardiovascular disease, chronic kidney disease, MASH, and sleep apnea. It also identifies gaps in national guidelines and reimbursement policies, emphasizing the need for stronger real-world evidence, updated clinical guidance, and policy reforms to improve equitable access

Join for free to read